Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1477-9560
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Differential impact of diabetes mellitus on antiplatelet effects of prasugrel and clopidogrel ; volume:16 ; number:1 ; day:15 ; month:3 ; year:2018 ; pages:1-9 ; date:12.2018
Thrombosis journal ; 16, Heft 1 (15.3.2018), 1-9, 12.2018
- Keyword
-
Biopharmazie
Pharmakodynamik
Pharmakokinetik
- Creator
-
Niijima, Satoshi
- Contributor
-
Ohmori, Tsukasa
Kario, Kazuomi
SpringerLink (Online service)
- DOI
-
10.1186/s12959-017-0159-8
- URN
-
urn:nbn:de:1111-2018031926490
- Rights
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 11:00 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Niijima, Satoshi
- Ohmori, Tsukasa
- Kario, Kazuomi
- SpringerLink (Online service)
Other Objects (12)
Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance - The BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy
Influence of genetic polymorphisms in P2Y12 receptor signaling pathway on antiplatelet response to clopidogrel in coronary heart disease
Platelet Survival and Antiplatelet Drugs in Diabetes Mellitus Disease
Impact of selected genetic factors on clopidogrel inactive metabolite level and antiplatelet response in patients after percutaneous coronary intervention
Analysis of the effect of CYP2C19 gene properties on the anti-platelet aggregation of clopidogrel after carotid artery stenting under network pharmacology
Influence of cytochrome P450 polymorphisms on the antiplatelet effects of prasugrel in patients with non-cardioembolic stroke previously treated with clopidogrel
Antiplatelet agents
A novel AllGlo probe-quantitative PCR method for detecting single nucleotide polymorphism in CYP2C19 to evaluate the antiplatelet activity of clopidogrel
European NSTEMI guidelines—return of clopidogrel?
Being Overweight or Obese Is Associated with an Increased Platelet Reactivity Despite Dual Antiplatelet Therapy with Aspirin and Clopidogrel
Antiplatelet Activity of Suloctidil I.V. Perfusion
In-vitro antiplatelet effect of melatonin in healthy individuals and patients with type 2 diabetes mellitus
Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance - The BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy
Influence of genetic polymorphisms in P2Y12 receptor signaling pathway on antiplatelet response to clopidogrel in coronary heart disease
Platelet Survival and Antiplatelet Drugs in Diabetes Mellitus Disease
Impact of selected genetic factors on clopidogrel inactive metabolite level and antiplatelet response in patients after percutaneous coronary intervention
Analysis of the effect of CYP2C19 gene properties on the anti-platelet aggregation of clopidogrel after carotid artery stenting under network pharmacology
Influence of cytochrome P450 polymorphisms on the antiplatelet effects of prasugrel in patients with non-cardioembolic stroke previously treated with clopidogrel
Antiplatelet agents
A novel AllGlo probe-quantitative PCR method for detecting single nucleotide polymorphism in CYP2C19 to evaluate the antiplatelet activity of clopidogrel
European NSTEMI guidelines—return of clopidogrel?
Being Overweight or Obese Is Associated with an Increased Platelet Reactivity Despite Dual Antiplatelet Therapy with Aspirin and Clopidogrel
Antiplatelet Activity of Suloctidil I.V. Perfusion
In-vitro antiplatelet effect of melatonin in healthy individuals and patients with type 2 diabetes mellitus
Tailored antiplatelet therapy can overcome clopidogrel and aspirin resistance - The BOchum CLopidogrel and Aspirin Plan (BOCLA-Plan) to improve antiplatelet therapy
Influence of genetic polymorphisms in P2Y12 receptor signaling pathway on antiplatelet response to clopidogrel in coronary heart disease
Platelet Survival and Antiplatelet Drugs in Diabetes Mellitus Disease
Impact of selected genetic factors on clopidogrel inactive metabolite level and antiplatelet response in patients after percutaneous coronary intervention
Analysis of the effect of CYP2C19 gene properties on the anti-platelet aggregation of clopidogrel after carotid artery stenting under network pharmacology
Influence of cytochrome P450 polymorphisms on the antiplatelet effects of prasugrel in patients with non-cardioembolic stroke previously treated with clopidogrel
Antiplatelet agents
A novel AllGlo probe-quantitative PCR method for detecting single nucleotide polymorphism in CYP2C19 to evaluate the antiplatelet activity of clopidogrel
European NSTEMI guidelines—return of clopidogrel?
Being Overweight or Obese Is Associated with an Increased Platelet Reactivity Despite Dual Antiplatelet Therapy with Aspirin and Clopidogrel
Antiplatelet Activity of Suloctidil I.V. Perfusion